The Convergence of Conventional Therapeutic Drug Monitoring and Pharmacogenetic Testing in Personalized Medicine: Focus on Antidepressants
- 28 March 2007
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 81 (6) , 899-902
Abstract
The development and prospects of conventional therapeutic drug monitoring (TDM) and pharmacogenetic testing as aids in personalized treatment with antidepressants and antipsychotics are described. Our own experience is discussed in relation to international guidelines for rational TDM. Emphasis is put on the usefulness of TDM combined with genotyping of cytochrome P450 2D6 (CYP2D6), the key enzyme involved in the polymorphic metabolism of the majority of antidepressants (both tricyclics and selective serotonin reuptake inhibitors) and antipsychotic drugs. This combination of methods is particularly useful in verifying concentration-dependent adverse drug reactions (ADRs) due to poor metabolism, 'and diagnosing pharmacokinetic reasons (ultrarapid metabolism (UM)) for drug failure. This is because ADRs may mimic the psychiatric illness itself and therapeutic failure due to UM may be mistaken for poor compliance with the prescription.Keywords
This publication has 26 references indexed in Scilit:
- The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in PsychiatryPharmacopsychiatry, 2004
- Therapeutic Drug Monitoring of Psychotropic DrugsTherapeutic Drug Monitoring, 2004
- Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseMolecular Psychiatry, 2004
- Cytochrome P450 Phenotyping/Genotyping in Patients Receiving AntipsychoticsClinical Pharmacokinetics, 2002
- Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patientsBritish Journal of Clinical Pharmacology, 2001
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complicationsThe Lancet, 1999
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977
- Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapyBMJ, 1969
- Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compoundsLife Sciences, 1967
- Genetic Control of Isoniazid Metabolism in ManBMJ, 1960